VU Research Portal

Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression

Cuijpers, P.; van Straten, A.; Warmerdam, L.; Andersson, G.

published in

Depression and Anxiety
2009

DOI (link to publisher)

[10.1002/da.20519](https://doi.org/10.1002/da.20519)

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Cuijpers, P., van Straten, A., Warmerdam, L., & Andersson, G. (2009). Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis. *Depression and Anxiety*, 26(3), 279-288. <https://doi.org/10.1002/da.20519>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

Research Article

PSYCHOTHERAPY VERSUS THE COMBINATION OF PSYCHOTHERAPY AND PHARMACOTHERAPY IN THE TREATMENT OF DEPRESSION: A META-ANALYSIS

Pim Cuijpers, Ph.D.,^{1*} Annemieke van Straten, Ph.D.,¹ Lisanne Warmerdam, M.A.,¹
and Gerhard Andersson, Ph.D.^{2,3}

Background: *A large number of studies have shown that psychological treatments have significant effects on depression. Although several studies have examined the relative effects of psychological and combined treatments, this has not been studied satisfactorily in recent statistical meta-analyses.* **Method:** *We conducted a meta-analysis of randomized studies in which a psychological treatment was compared to a combined treatment consisting of the same psychological treatment with a pharmacological therapy. For each of these studies we calculated the effect size indicating the difference between the psychological and the combined treatment.* **Results:** *All inclusion criteria were met by 18 studies, with a total of 1,838 subjects. The mean effect size indicating the difference between psychological and combined treatment was 0.35 (95% CI: 0.24~0.45; $P < 0.001$), with low heterogeneity. Subgroup analyses indicated that the difference between psychological and combined treatments was significantly smaller in studies in which cognitive behavior therapy was examined. We also found a trend ($P < 0.1$) indicating that the difference between psychological and combined treatment was somewhat larger in studies aimed at specific populations (older adults, chronic depression, HIV patients) than in studies with adults, and in studies in which Tricyclic antidepressants or SSRIs were examined, compared to studies in which a medication protocol or another antidepressant was used. At follow-up, no difference between psychological and combined treatments was found.* **Conclusion:** *We conclude that combined treatment is more effective than psychological treatment alone. However, it is not clear whether this difference is relevant from a clinical perspective.* *Depression and Anxiety 26:279–288, 2009.* © 2008 Wiley-Liss, Inc.

Key words: *depression; major depression; psychotherapy; combined treatment; meta-analysis*

¹Department of Clinical Psychology and EMGO Institute, VU University, Amsterdam, The Netherlands

²Department of Behavioural Sciences and Learning, Swedish Institute for Disability Research, Linköping University, Linköping, Sweden

³Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, Stockholm, Sweden

*Correspondence to: Pim Cuijpers, Ph.D., Professor of Clinical Psychology, Department of Clinical Psychology, Chair Vrije Universiteit, Amsterdam, Van der Boerhorststraat 1, 1081 BT Amsterdam, The Netherlands. E-mail: p.cuijpers@psy.vu.nl

Received for publication 10 September 2007; Revised 10 February 2008; Accepted 20 March 2008

DOI 10.1002/da.20519

Published online 21 November 2008 in Wiley InterScience (www.interscience.wiley.com).

INTRODUCTION

In the past three decades, at least 160 controlled and comparative studies have examined the effects of psychological treatments compared to control conditions and to other treatments.^[1] This large number of studies has clearly shown that most psychological treatments studied in a trial have large effects on depression. Psychological treatments that have proved effective include cognitive-behaviour therapy,^[2] behavioural activation treatments,^[3] interpersonal psychotherapy,^[4] problem-solving treatment^[5,6] and life review for older adults.^[7] These treatments are not only effective in adults with depression, but also in older adults,^[8] in women with postpartum depression,^[9] and in patients with both depression and general medical disorders, including multiple sclerosis,^[10] stroke patients,^[11] and cancer patients.^[12] Psychological treatments can be delivered effectively in group format, individual format, or guided self-help format.^[13,14] Probably, the latest contribution to this list is the provision of treatment via the Internet.^[15]

One group of studies has focused on the comparative effects of psychological and pharmacological treatments. This research has shown that the effects of both types of treatment are comparable.^[16] It is also clear that a combined treatment is somewhat more effective than treatment with pharmacotherapy alone.^[17,18] It is not very clear, however, whether combined treatment is more effective than a psychological treatment alone. Clinicians often have different views on this, in particular when it comes to more severe depression when combined treatments often are recommended.

Although several studies have examined the effects of combined treatment, the results are not entirely conclusive. Some studies find no significant difference.^[19–21] whereas others have found that combined treatment is significantly more effective than psychological treatment alone.^[23,24] There are even a few studies found that psychological treatment alone is more effective than combined treatment.^[25,26]

Because it can be expected that the difference between psychological and combined treatments are small, large sample sizes are required to find significant differences. When small effect sizes are expected in individual studies, meta-analytical techniques can be used to integrate the results of individual studies and to increase the statistical power. Although several systematic reviews have examined the difference between psychological and combined treatments,^[27,28] this question has not been examined in recent statistical meta-analyses using up-to-date methods. For example, one meta-analysis conducted in this area has included only a small portion of the available studies (8 of the 18 studies we have identified, see below.^[17] This meta-analysis also focused on several research questions, did not pool the results of all studies together, and did not for example conduct subgroup analyses to examine the characteristics of the studies, which were related to the

differential effects of the psychological and combined treatments. It did, however, find some indications that combined treatment was somewhat more effective than psychological treatment alone. Another small meta-analysis did examine the comparative effects of psychological versus combined treatment,^[29] but focused only on the seven studies that examined outpatients. This study also found that combined treatment was superior to psychological treatment alone.

We decided to conduct a new, comprehensive meta-analysis in which all available studies are included. We wanted to examine whether the small benefit of combined treatment, which was found in the earlier meta-analyses,^[17,29] would also be found when the number of examined studies was increased. Finally, we wanted to examine whether study characteristics were related to the relative effects of psychological and combined treatments.

METHODS

IDENTIFICATION AND SELECTION OF STUDIES

First, we used a large database of studies on the psychological treatment of depression in general. This database has been described in detail elsewhere.^[3,5,6,8] It was developed through a comprehensive literature search (from 1966 to December 2007) in which we examined 7,911 abstracts in Pubmed (1,403 abstracts), Psycinfo (2,097), Embase (2,207), and the Cochrane Central Register of Controlled Trials (2,204). We identified these abstracts by combining terms indicative of psychological treatment (psychotherapy, psychological treatment, cognitive therapy, behaviour therapy, interpersonal therapy, counselling, family therapy, marital therapy, problem-solving therapy, psychodynamic therapy, psychoanalysis, relaxation, reminiscence, life review) and depression (both MeSH-terms and textwords). For this database, we also collected the primary studies from 22 meta-analyses of psychological treatment of depression.^[1] We retrieved a total of 857 papers for further study. These papers were studied, and we selected the ones which examined the relative effects of psychological and combined treatments of depression.

Second, references of earlier reviews and meta-analyses were examined.^[1,16–18,27–28] Finally, the references of retrieved papers were checked.

We included studies in which (1) a psychological intervention (2) was compared to a combined treatment (3) consisting of the same psychological intervention plus an antidepressant, (4) in a randomized trial, (5) aimed at subjects with depression (as diagnosed through a clinical interview and/or a self-report questionnaire). Psychological interventions were defined as treatments in which verbal communication between a therapist and a client was the core element and in which the communication of the therapist is based on a specific theoretical framework about the causes of depression and how the communication can reduce it. Studies were included when all randomized participants had a depressive disorder (or scored above a cut-off point on a self-report instrument); comorbid general medical or psychiatric disorders were not used as an exclusion criterion. No language restrictions or age limits were applied. We excluded studies on maintenance treatments and studies in which a psychological treatment plus placebo were compared to a psychological treatment plus active antidepressant, because it cannot be ruled out that the placebo has an effect in itself.

QUALITY ASSESSMENT

At least 25 scales have been used to assess the validity and quality of RCTs,^[30] but evidence of their reliability and validity is lacking. We adopted the Cochrane Handbook's 4 criteria,^[30] to assess study validity: (1) randomization to conditions conducted by an independent (third) party; (2) concealment of randomization to conditions; (3) blinding of assessors of outcome; (4) completeness of follow-up data.

ANALYSES

We directly compared the psychological and combined treatments on depressive symptomatology (continuous outcomes), recovery (dichotomous outcomes), and drop-out.

Effects on depressive symptomatology (continuous outcomes). We calculated effect sizes indicating the difference between psychological and combined treatments. The effect sizes (d) were calculated by subtracting (at post-test) the average score of the psychological treatment group (M_p) from the average score of the combined treatment group (M_c) and dividing the result by the pooled standard deviations of the experimental and control groups (SD_{pc}). An effect size of .5 thus indicates that the mean of the psychological treatment group is half a standard deviation larger than the mean of the combined treatment group. Effect sizes of .8 can be assumed to be large, whereas effect sizes of .5 are moderate, and effect sizes of .2 are small.^[31] In the calculations of effect sizes, only those instruments were used that explicitly measure depression (Table 1). If more than one depression measure was used, the mean of the effect sizes was calculated, so that each study (or contrast group) had only one effect size. When means and standard deviations were not reported, we used other statistics (t -value, p -value) to calculate effect sizes.

To calculate pooled mean effect sizes, we used the computer program Comprehensive Meta-analysis (version 2.2.021), developed for support in meta-analysis. We conducted all analyses using both the fixed effects model and the random effects model.^[25] As an indicator of homogeneity, we calculated the Q -statistic. We also calculated the I^2 -statistic, which is an indicator of heterogeneity in percentages. A value of 0% indicates no observed heterogeneity, and larger values show increasing heterogeneity, with 25% as low, 50% as moderate, and 75% as high heterogeneity.

Subgroup analyses. We examined whether specific characteristics of the studies were related to the effect sizes by using the procedures for subgroup analyses as implemented in Comprehensive Meta-analysis. In these analyses we used the mixed effects model. This means that the random effects model is used to calculate the effect size for each subgroup, whereas the fixed effects model tests the difference between the subgroups of studies.

We conducted subgroup analyses on the selected characteristics of the three core elements of the studies: participants, interventions, and study characteristics. With regard to the participants we examined the recruitment method (clinical samples versus other samples) and target group (adults in general versus specific population). We also examined the type of psychological intervention (CBT versus other types of psychological treatments) and the type of pharmacological treatment (tricyclics, SSRIs, or other). General characteristics of the studies we reviewed in subgroup analyses were: drop out rate (less than 20% drop-out versus 20% or more drop-out), type of analyses (intention-to-treat analyses versus completers-only analyses), and the period in which the study was conducted (before 1995 versus 1995 or later).

Effects on recovery (dichotomous outcomes). We calculated the relative risk (RR) of recovery in subjects receiving psychological treatment compared to subjects receiving combined treatment. Again, we conducted all meta-analyses both with the fixed

effects model and with the random effects model, using the Comprehensive Meta-analysis (version 2.2.021) computer program, and we calculated the Q -statistic and the I^2 -statistic to estimate heterogeneity between study outcomes.

Publication bias. Publication bias was tested by inspecting the funnel plot on primary outcome measures, and by Duval and Tweedie's trim and fill procedure, which yields an estimate of the effect size after the publication bias has been taken into account (as implemented in Comprehensive Meta-analysis, version 2.2.021).

We also calculated "Orwin's fail safe N ." This number indicates how many studies with an effect size of zero should be found to reduce the effect size that is found to a lower value (for example, .10). A larger N indicates that the effect size found can be further generalized.

RESULTS

DESCRIPTION OF INCLUDED STUDIES

All inclusion criteria were met by 19 studies, with a total of 1,838 subjects (934 in the psychological treatment groups, and 904 in the combined treatment groups). Selected characteristics of these studies are described in Table 1.

Fourteen studies were aimed at adults in general, and five at specific populations (two at adults with HIV; one focused on multiple sclerosis patients; one on adults with chronic depression; and one on older adults). Eleven studies were aimed at clinical populations, six at subjects recruited from the community, and two did not report the recruitment method or they used systematic screening to recruit patients. In all but one study only subjects who met diagnostic criteria for a depressive disorder (including two studies specifically aimed at patients with dysthymia) were included. In eight studies, CBT was used as psychological treatment. In three studies, amitriptyline was used as the antidepressant medication, in three other studies imipramine was used, a further three had desipramine, two had fluoxetine, and the remaining 12 used another medication or used more than one type of medication. Six studies were conducted before 1990, five between 1990 and 1999, and the remaining eight after 2000. Seventeen studies were published in English, one in Spanish, and one in German.

QUALITY OF THE INCLUDED STUDIES

The quality of the studies varied. Only four studies reported that allocation to conditions was conducted by an independent party. Concealment of random allocation to respondents was not possible or not reported in any of the studies, whereas blinding of assessors was reported in 11 studies. Drop-out numbers ranged from 6 to 55%.

CONTINUOUS OUTCOMES AT POST-TEST

In 17 studies (19 comparisons), effect sizes could be calculated which indicated the difference between psychological and combined treatments at post-test.

TABLE 1. Selected studies of randomized studies comparing the effects of psychological treatment to the effects of combined treatment

Study	Population			Psychological treatment			Combined treatment			Study		
	General	Recr	Definition depression	Type	N _{ses}	N _{rsp}	AD	N _{rsp}	Measure-ments	Instruments	Country	DO (%)
Beck et al. ^[34]	Adults	Comm + Clin	BDI > 20 + HRSD > 14 + DD (FC)	CBT	20	18	CBT + amitriptyline	15	Pre, post, 6, 12 mn	BDI, HRSD	US	24
Blackburn et al. ^[35]	Adults	Clin	MDD (SADS / RDC)	CBT	15	22	CBT + drug of choice	22	Pre, post	BDI, HRSD	UK	27
Browne et al. ^[36]	Adults	Comm	DYST (DSM-IV / UMI-CIDI)	IPT	10	178	IPT + Sertraline	212	Pre, post	MADRS, CES-D, VAS	CAN	17
De Jonghe et al. ^[22]	Adults	Clin	MDD (DSM-IV) + HRSD 12-24	Psychodyn ther	16	106	Psychodyn ther + AD	85	Pre, post	HRSD; SCL-90-d	NL	NR
Hautzinger et al. ^[32]	Adults	Clin	MDD or DYST + HDRS > 20 + BDI > 20	CBT	24	70	CBT + amitriptyline	68	Pre, post	HRSD, BDI	GER	30
Hollon et al. ^[37]	Adults	Clin	MDD (RDC) + BDI > 20 + HRSD > 14	CBT	20	25	CBT + imipramine	25	Pre, post	HRSD, BDI, RDS, MMPI-d	US	40
Keller et al. ^[24]	Adults with chronic depression	Clin	MDD + dysth OR recurr + HRSD > 20	CBASP	18	228	CBASP + Nefazodone	227	Pre, post	HRSD	US	24
Lopez-Rodriguez et al. ^[38]	Adults	Clin	DD (DSM-IV)	Bellaks' psychother	NR	10	Bellaks' psychother + fluoxetine	10	Pre, post	HRSD	MEX	NR
Markowitz et al. ^[39]	Adults with HIV	Comm	HRSD > 15	Supportive psychother	8-16	24	Supp. Ther + imipramine	26	Pre, post	HRSD, BDI	US	32
Markowitz et al. 2005	Adults	Comm	Dysthymia (SCID)	IPT	17	23	IPT + Sertraline	21		HRSD, BDI, CDRS	US	18
Murphy et al. ^[19]	Adults	Clin	MDD (Feighner) + BDI > 20 + HRSD > 14	CT	20	24	CT + nortriptyline	22	Pre, post, 1 mn	HRSD, BDI	US	26
Mynors-Wallis et al. ^[33]	Adults	Clin - GP	MDD (RDC)	PST (by GP OR nurse)	6	39 + 41	PST + fluvoxamine OR paroxetine	35	Pre, post, 12 mn	HRSD, BDI, CIS	UK	6
Roth et al. ^[40]	Adults	Comm	MDD (RDC) + BDI > 18 + HRSD > 15	Self-control ther.	12	13	Self-control ther. + desipramine	13	Pre, post, 3 mn	HRSD, BDI	US	19
Rush and Watkins ^[41]	Adults	Nr	MDD (DSM-III) + BDI > 20 + HRSD > 14	CBT	20	9	CBT + AD	7	Pre, post	HRSD, BDI, MMPI-d	US	14
Schiffer and Watkins ^[42]	Multiple sclerosis patients	Screening	MDD (SADS / RDC)	Brief psychother	5	14	Brief psychother + desipramine	14	Pre, post	HRSD, BDI	US	12
Stravynski, ^[43]	Adults	Clin	MDD (DSM-III-R) + BDI > 20 + HRSD > 14	Group CBT	15	12	Group CBT + imipramine	12	Pre, post	HRSD, BDI	CAN	25
Thompson et al. ^[21]	Older adults (> 60 years)	Comm	MDD (SADS / RDC) + HRSD > 14 + BDI > 16	CBT	18	31	CBT + desipramine	36	Pre, post	HRSD, BDI	US	30
Weissman et al. ^[44]	Adults	Clin	MDD (SADS / RDC) + RDS > 7	IPT	16	24	IPT + amitriptyline	24	Pre, post	RDS	US	55
Zisook et al. ^[45]	HIV patients	Clin	MDD (DSM-III-R / SCID)	Group supp. Ther	8	22	Group supp ther + fluoxetine	25	Pre, post	HRSD, BDI	US	21

¹⁾Abbreviations (alphabetical): Activ sched: activity scheduling; AD: antidepressant medication; AUS: Australia; CAN: Canada; CBASP: cognitive behavioural-analysis system of psychotherapy; CBT: cognitive-behaviour therapy; Clin: clinical recruitment; Comm: community recruitment; DO: drop-out; GER: Germany; GP: general practitioner; IPT: interpersonal psychotherapy; Mar ther: marital therapy; MDD: major depressive disorder; MEX: Mexico; Mn: months; NL: The Netherlands; NR: not reported; N_{ses}: number of respondents; N_{rsp}: number of sessions; PLA: placebo; PST: problem-solving therapy; Psychodyn: psychodynamic; Psychother: psychotherapy; Recr: recruitment; Soc. skills tr: social skills training; Supp: support; Ther: therapy; UK: United Kingdom; US: United States of America.

TABLE 2. Meta-analyses of studies comparing the effects of psychological treatments on depression compared to combined treatments at post-test: continuous outcomes

Study		N_{comp}	D	95% CI	Z	Q^a	I^2	P
Overall effects								
All studies	Fixed/random effects ^b	19	0.35	0.24–0.45	6.67***	15.85	0	
All studies without Keller	Fixed/random effects ^b	18	0.27	0.15–0.39	4.37***	10.18	0	
Only HRSD	Fixed effects	17	0.35	0.24–0.46	6.24***	19.73	18.91	
	Random effects		0.31	0.18–0.45	4.59***			
Only BDI	Fixed/random effects ^b	15	0.28	0.12–0.43	3.55***	9.86	0	
Subgroup analyses ^c								
Target group	Adults	14	0.24	0.10–0.37	3.49***	4.06	0	o
	Specific groups	5	0.49	0.27–0.71	4.29***	5.21	23.25	
Recruitment	Clinical	11	0.39	0.27–0.51	6.31***	8.46	0	n.s.
	Other	8	0.24	0.05–0.43	2.53*	5.64	0	
Psychological treatment	CBT	8	0.15	–0.06–0.37	1.39	1.97	0	*
	Other	11	0.40	0.29–0.52	6.82***	9.95	0	
Year of publication	Before 1995	7	0.22	–0.05–0.49	1.60	2.55	0	n.s.
	1995 or later	12	0.35	0.23–0.47	5.62***	12.35	10.92	
Drop-out rate ^d	< 20%	7	0.24	0.06–0.43	2.59*	2.25	0	n.s.
	> 20%	10	0.36	0.18–0.53	4.06***	11.04	18.50	
Analyses	Intention-to-treat	12	0.39	0.26–0.52	6.00***	11.15	1.34	n.s.
	Completers-only	7	0.25	0.08–0.43	2.82**	3.04	0	
Medication category	Tricyclics	10	0.22	0.02–0.41	2.21*	5.47	0	o
	SSRIs	6	0.27	0.08–0.45	2.83**	3.82	0	
	Other	3	0.49	0.33–0.64	6.10***	0.94	0	
Effects at follow-up								
3–6 months	Fixed + random ^b	3	–0.15	–0.58–0.27	–0.71 n.s.	0.01	0	
12 months	Fixed + random ^b	5	0.00	–0.26–0.26	0.01 n.s.	1.87	0	

o: $P < 0.10$; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.

^aThe results for the random effects model and the fixed effects model were identical.

^bAll subgroup analyses were conducted with mixed effects analyses.

^cNone of the Q -values was significant ($P > 0.05$).

^dthe two studies in which the drop-out rates were not reported were not included in these analyses.

The mean effect size indicating the difference between psychological and combined treatments was .35 (95% CI: .24~.45; $P < .001$) both in the fixed and the random effects model. Heterogeneity was very low ($Q = 15.85$ n.s.; $I^2 = 0$). The results of these analyses are summarized in Table 2 and Figure 1.

Because the weight of one study was very high^[21] (28.50%), we also conducted a meta-analysis in which this study was removed. The results were almost the same (fixed effects and random effects model: $d = .27$; 95% CI: .15~.39, $P < .001$; $I^2 = 0$).

Two studies contained more than one comparison of a psychological versus a combined treatment.^[32,33] We included the four comparisons from these studies in our meta-analysis. Because these comparisons were not independent of each other, we examined whether this influenced the outcomes. We conducted a new meta-analysis in which only the smallest effect size from each of these two studies was included, but found that this scarcely influenced the results (fixed effects and random effects model: $D = 0.36$; 95% CI: .25~.46; $Z = 6.56$, $P < .001$; $Q = 15.39$ n.s.; $I^2 = 0$).

In 15 studies (17 comparisons), the Hamilton Rating Scale for Depression (HRSD) was used. When only this scale was used for the calculation of the effect sizes,

a mean effect size of .35 (95% CI: .24~.46) was found with the fixed effects model, and .31 (95% CI: .18~.45) with the random effects model (with low heterogeneity: $Q = 19.73$ n.s.; $I^2 = 18.91$). The fifteen comparisons using the Beck Depression Inventory (BDI) resulted in a mean effect size of 0.28 (95% CI: 0.12~0.43), both with the fixed and the random effects model ($Q = 9.86$, n.s.; $I^2 = 0$).

SUBGROUP ANALYSES

We conducted several subgroup analyses (Table 2). No significant difference was found between the effect size of studies in which clinically referred patients were examined and those in which subjects were recruited in other ways (mostly through community recruitment). We also found no difference between older (<1995) and newer (>1995) studies; between studies which used intention-to-treat analyses and those using completers-only analyses; and between studies with a drop-out rate below 20% and those with a drop-out rate of 20% or higher.

We found a significant difference ($P < .05$) between studies which used cognitive behavioural intervention and those in which other types of psychological

Figure 1. Standardized effect sizes of psychological treatment for depression compared to combined treatment at post-test: Continuous outcomes

treatments were found (Table 2). For that comparison the advantage of combination was less when medication was added to CBT. We also found a trend showing that studies using tricyclic medications or SSRIs were used had smaller effect sizes than studies using another medication (nefazodone)^[24] or more than one type of medication.^[22,41]

We found a trend ($P < .1$) indicating a significant difference between studies aimed at adults with depression and the effect size of studies targeting specific populations (two studies on HIV-patients; one study on adults with chronic depression, one on patients with multiple sclerosis, and one study on older adults).

DICHOTOMOUS OUTCOMES AT POST-TEST

The RR indicating the difference between psychological and combined treatments in recovery was .78 (95% CI: .71~0.860; 17 comparisons; $Z = -4.91$; $P < .001$), both in the fixed and the random effects model. Heterogeneity was low ($Q = 12.90$; n.s.; $I^2 = 0$). The results of these analyses are summarized in Table 3 and Figure 2.

We conducted the same subgroup analyses as with the continuous outcomes (Table 3). However, none of the variables we examined in these analyses resulted in a significant difference between subgroups (including the three variables that were found to be significant in the analyses with the continuous outcomes).

PUBLICATION BIAS

Neither the funnel plots nor Duval and Tweedie's trim and fill procedure pointed at a significant publication bias. And this was true both in the analyses with the continuous outcomes and in the analyses with the dichotomous outcomes. The effect size indicating the difference in depressive symptomatology between psychological treatment and combined treatment conditions did not change after adjustment for possible publication bias (the observed and adjusted d were identical), and this was also true for the RR indicating the difference between psychological and combined treatments.

We then calculated Orwin's fail-safe N , which is the number of studies with an effect size of zero that should be found to reduce the mean effect size (indicating the difference between psychological and combined treatments) to .10; this was found to be 44. The number of studies (with an RR of 1) needed to reduce the RR from 0.78 to 0.90 was found to be 24.

EFFECTS AT FOLLOW-UP

In seven studies (10 comparisons) the difference between psychological and combined treatments at follow-up were presented. The results of these analyses are presented in Table 2. The follow-up periods ranged from 1 month to 2 years. As there was only one study which reported the results at 2-year follow-up, this study was not included in the analyses. Nor did we include the study in which a follow-up of one month was used.

TABLE 3. Meta-analyses of studies comparing the effects of psychological treatments on depression compared to combined treatments at post-test: Dichotomous outcomes

Study		N	RR	95% CI	Z	Q ^a	I ²	P
Overall effects								
All studies	Fixed/random effects ^b	17	0.78	0.71–0.86	−4.91***	12.90	0	
Subgroup analyses^c								
Target group	Adults	13	0.82	0.73–0.92	−3.50***	8.78	0	n.s.
	Specific groups	4	0.67	0.55–0.82	−3.81***	1.43	0	
Recruitment	Clinical	10	0.78	0.69–0.88	−4.02***	3.21	0	n.s.
	Other	7	0.71	0.49–1.02	−1.86	9.68	38.04	
Psychological treatment	CBT	6	0.85	0.68–1.07	−1.40	5.78	13.44	n.s.
	Other	11	0.76	0.68–0.85	−4.76***	6.11	0	
Year of publication	Before 1995	8	0.83	0.67–1.02	−1.81	6.73	0	n.s.
	1995 or later	9	0.77	0.68–0.86	−4.61***		0	
Drop-out rate ^d	< 20%	7	0.80	0.68–0.93	−2.92**	4.25	0	n.s.
	> 20%	9	0.77	0.67–0.90	−3.41**	8.52	6.06	
Analyses	Intention-to-treat	10	0.74	0.64–0.85	−4.24***	6.67	0	n.s.
	Completers-only	7	0.82	0.72–0.95	−2.69**	5.06	0	
Medication category	Tricyclics	9	0.82	0.69–0.98	−2.15*	7.66	0	n.s.
	SSRIs	5	0.80	0.69–0.94	−2.82**	2.76	0	
	Other	3	0.70	0.58–0.85	−3.63***	0.77	0	

* $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.

^aThe fixed effects model and the random effects model resulted in the same outcomes.

^bAll subgroup analyses were conducted with mixed effects analyses.

^cNone of the Q-values was significant.

^dThe study in which the drop-out rates was not reported, was not included in these analyses.

Figure 2. Standardized effect sizes of psychological treatment for depression compared to combined treatment at post-test: Dichotomous outcomes

None of the analyses indicated a significant difference between psychological and combined treatments at 3–6 months follow-up, and at 12 months follow-up. Because of the small number of comparisons and the differences in follow-up periods, we did not analyse the results at follow-up any further.

DISCUSSION

We found clear evidence that a combined psychological and pharmacological treatment of depression is superior to psychological treatment alone in the short term. This was true when we pooled different effect

sizes, but also when we examined specific outcome measures. Heterogeneity was low in these analyses, indicating that the studies, target populations, and interventions are probably highly comparable to each other. We found no indication of publication bias, and fail-safe analyses showed that a large number of studies with no difference would have to be found to reduce the overall effects on a nonsignificant outcome. Therefore, there should be little doubt that there is indeed a difference in effects between psychological and combined treatments. Because the effect size indicating the difference between psychological and combined treatments was small to moderate, several individual studies failed to find a significant difference, and it is a clear advantage of a meta-analytic approach that makes it possible to combine the results of multiple studies and validate such small effect sizes.

However, the effect size indicating the difference between psychological and combined treatments is small to moderate. Effect sizes lower than 0.30 are usually considered to be small, and our effect size was only just above that threshold ($d = 0.35$). Although our finding was statistically significant, it is not clear whether this has any clinical relevance. To obtain an idea of the clinical relevance of these effect sizes, the use of the binomial effect size display is recommended.^[46,47] This displays the difference in success rate between the two treatments. When we compare psychological treatment to combined treatment, the binomial effect size display (based on $d = .35$) indicates that the success rate increases from .41 to .59. This suggests that combined treatment is superior for some patients and that combined treatment should be offered to patients before psychological treatment alone is considered.

However, these results should be considered with caution. In our study, we did not examine the comparative effects of pharmacotherapy and combined treatment. Several studies have found that combined treatment is more effective than pharmacotherapy alone.^[21,33,48,49] If this is indeed the case, then combined treatment should be considered as a first line treatment, as it is superior to both psychological treatment alone and pharmacological treatment alone. However, if pharmacotherapy appears to be equally effective as combined treatment, it may be better to consider pharmacotherapy first and only offer combined treatment when pharmacotherapy alone does not work. Because many patients prefer psychological treatments and are not willing to take antidepressants,^[50] psychological treatments (without additional pharmacotherapy) will remain an important part of routine care, even when combined treatments are clearly superior. More (meta-analytic) research is needed to examine these questions.

One reason why the suggested superiority of combined over psychological treatment alone should be considered with caution is that no difference was found in the longer term. This is probably at least in

part related to the small number of available effect sizes at follow-up. It does mean that there is currently no evidence that combined treatment is superior to psychological treatment alone in the longer term.

Our findings should also be considered in the light of the study's limitations. First, we found that the quality of a number of the examined studies was not optimal. Although it is clearly inherent in studies of research on psychological treatments that it is not possible to conceal to subjects to which condition they are assigned, many studies did not meet other major quality criteria, such as assignment to conditions by an independent person, and blinding of assessors. Another important limitation of this meta-analysis is that we were only able to include a relatively small number of studies. Therefore, the results of our analyses should be considered very cautiously.

This meta-analysis only reports about average effects. However, the average patient does not exist, and it is entirely possible that different types of patients are best served by different treatment strategies. One finding of this study is research on specific populations found significantly larger differences between psychological and combined treatments than studies in adult outpatients. It is possible that psychological treatments are less effective in some of these populations, which increases the effects of the added pharmacological treatments. But it also possible that the relative effects of psychological and combined treatments are related to severity, chronicity, and comorbid psychiatric or general medical disorder. More research is needed to examine these issues.

We found a trend indicating that the difference between psychological and combined treatments is smaller when cognitive behavioral therapy is used compared to other psychological treatments. It could be possible that cognitive behavioral treatments have stronger effects than other psychological treatments. In that case, the additional value of the pharmacological treatment may be limited. Although there is some evidence that cognitive behavioral treatments are more effective than other treatments,^[2,51] the evidence is certainly not conclusive.^[52]

Although we did find that combined treatment is more effective than psychological treatment alone, more research is needed to examine this difference. Further research is called for on the relative efficacy of psychological and combined treatments in the longer term. More basic research is needed required to explore the mechanisms through which both treatments work. And more clinical research is necessary to examine which treatment or combination of treatments is effective at in the longer term.

REFERENCES

1. Cuijpers P, Dekker J. 2005. Psychologische behandeling van depressie: een systematisch overzicht van meta-analyses. *Ned Tijdschr Geneesk* 149:1892–1897.

2. Gloaguen V, Cottraux J, Cucherat M, Blackburn IM. A meta-analysis of the effects of cognitive therapy in depressed patients. *J Affect Dis* 1998;49:59–72.
3. Cuijpers P, van Straten A, Smit F. Psychological treatment of late-life depression: a meta-analysis of randomized controlled trials. *Int J Geriatr Psychiatry* 2006a;21:1139–1149.
4. Churchill R, Hunot V, Corney R, et al. A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression. *Health Technol Assess* 2001;5:35.
5. Cuijpers P, van Straten A, Warmerdam L. Problem solving therapies for depression: a meta-analysis. *Eur Psychiatry* 2007;22:9–15.
6. Cuijpers P, van Straten A, Warmerdam L. Behavioral treatment of depression: a meta-analysis of activity scheduling. *Clin Psychol Rev* 2007;27:318–326.
7. Bohlmeijer E, Smit F, Cuijpers P. Effects of reminiscence and life-review on late-life depression: a meta-analysis. *Int J Geriatr Psychiatry* 2003;18:1088–1094.
8. Cuijpers P, van Straten A, Smits N, Smit F. Screening and early psychological intervention for depression in schools: systematic review and meta-analysis. *Eur Child Adol Psychiatry* 2006b;15:300–307.
9. Lumley J, Austin MP, Mitchell C. Intervening to reduce depression after birth: A systematic review of the randomized trials. *Int J Technol Assess Health Care* 2004;20:128–144.
10. Mohr DC, Goodkin DE. Treatment of depression in multiple sclerosis: review and meta-analysis. *Clin Psychol Sc Pract* 1999;6:1–9.
11. Hackett ML, Anderson CS, House AO. Interventions for treating depression after stroke. *Cochrane Database of Systematic Reviews* Issue 2004;2 Art No: CD003437pub2. DOI: 10.1002/14651858CD003437pub2.
12. Sheard T, McGuire P. The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. *Br J Cancer* 1999;80:1770–1780.
13. McDermut W, Miller IW, Brown RA. The efficacy of group psychotherapy for depression: A meta-analysis and review of the empirical research. *Clin Psychol Sc Pract* 2001;8:98–116.
14. Cuijpers P. Bibliotherapy in unipolar depression. *J Behav Ther Exp Psychiatry* 1997;28:139–147.
15. Spek V, Cuijpers P, Nyklíček I, Riper H, Keyzer J, Pop V. Internet-based cognitive behavior therapy for mood and anxiety disorders: a meta-analysis. *Psychol Med* 2007;37:319–328.
16. Robinson LA, Berman JS, Neimeyer RA. Psychotherapy for the treatment of depression: a comprehensive review of controlled outcome research. *Psychol Bull* 1990;108:30–49.
17. Friedman MA, Detweiler-Bedell JB, Leventhal HE, Horne R, Keitner GI, Miller IW. Combined psychotherapy and pharmacotherapy for the treatment of major depressive disorder. *Clin Psychol Sc Pract* 2004;11:47–68.
18. Pampanolla S, Bollini P, Tibaldi G, Kupelnick B, Munizza C. Combined pharmacotherapy and psychological treatment for depression; a systematic review. *Arch Gen Psychiatry* 2004;61:714–719.
19. Murphy GE, Simons AD, Wetzel RD, Lustman PJ. Cognitive therapy and pharmacotherapy singly and together in the treatment of depression. *Arch Gen Psychiatry* 1984;41:33–41.
20. Schmitz JM, Averill P, Stotts AL, Moeller FG, Rhoades HM, Grabowski J. Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. *Drug Alc Dep* 2001;63:207–214.
21. Thompson LW, Coon DW, Gallagher-Thompson, D, Sommer BR, Koin D. Comparison of desipramine and cognitive/behavioral therapy in the treatment of elderly outpatients with mild-to-moderate depression. *Am J Geriatr Psychiatry* 2001;9:225–240.
22. De Jonghe F, Hendricksen M, van Aalst G, et al. Psychotherapy alone and combined with pharmacotherapy in the treatment of depression. *Br J Psychiatry* 2004;185:37–45.
23. Ravindran AV, Anisman H, Merali Z, Charbonneau Y, Telner J, Bialik RJ, et al. Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: clinical symptoms and functional impairments. *Am J Psychiatry* 1999;156:1608–1617.
24. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. *New Engl J Med* 2000;342:1462–1470.
25. Hersen M, Bellack AS, Himmelhoch JM, Thase ME. Effects of social skills training, amitriptyline, and psychotherapy in unipolar depressed women. *Behav Ther* 1985;15:21–40.
26. Friedman AS. Interaction of drug therapy with marital therapy in depressive patients. *Arch Gen Psychiatry* 1975;32:619–637.
27. Wexler BE, Cicchetti DV. The outpatient treatment of depression: implications of outcome research for clinical practice. *J Nerv Ment Dis* 1992;180:277–286.
28. Jindal RD, Thase ME. Integrating psychotherapy and pharmacotherapy to improve outcomes among patients with mood disorders. *Psychiatr Serv* 2003;54:1484–1490.
29. De Maat S, Dekker J, Schoevers RA, de Jonghe F. Relative efficacy of psychotherapy and combined therapy in the treatment of depression: a meta-analysis. *Eur Psychiatry* 2007;22:1–8.
30. Higgins JPT, Green S. *Cochrane Handbook for Systematic Reviews of Interventions* 4.2.6 [updated September 2006]. In: *The Cochrane Library*, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd; 2006.
31. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. 2nd ed. Hillsdale, NJ: Erlbaum; 1988.
32. Hautzinger M, de Jong-Meyer R, Treiber R, Rudolf, GAE, Thien U. Wirksamkeit Kognitiver Verhaltenstherapie, Pharmakotherapie und deren Kombination bei nicht-endogenen, unipolaren Depressionen. *Zeitschr Klin Psychol* 1996;25:130–145.
33. Mynors-Wallis, LM, Gath DH, Day A, Baker F. Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. *BMJ* 2000;320:26–30.
34. Beck AT, Hollon SD, Young JE, Bedrosian RC, Budenz D. Treatment of depression with cognitive therapy and amitriptyline. *Arch Gen Psychiatry* 1985;42:142–148.
35. Blackburn IM, Bishop S, Glen AL, Whalley LJ, Christie JE. The efficacy of cognitive therapy in depression: a treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination. *Br J Psychiatry* 1981;139:181–189.
36. Browne G, Steiner M, Roberts J, et al. Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. *J Affect Dis* 2002;68:317–330.
37. Hollon SD, DeRubeis RJ, Evans MD, et al. Cognitive therapy and pharmacotherapy for depression: singly and in combination. *Arch Gen Psychiatry* 1992;49:774–781.
38. Lopez Rodriguez J, Lopez Butron MA, Vargas Terrez BE, Salcedo V. Estudio doble ciego con antidepressivo, psicoterapia breve y placebo en pacientes con depresión leve a moderada. *Salud Mental* 2004;27:53–61. [Double blind study with antidepressant, brief psychotherapy and placebo in patients with mild to moderate depression]
39. Markowitz JC, Kokcis JH, Fishman B, et al. Treatment of depressive symptoms in human immunodeficiency virus — positive patients. *Arch Gen Psychiatry* 1998;55:452–457.

40. Roth D, Bielski R, Jones M, Parker W, Osborn G. A comparison of self-control therapy and combined self-control therapy and anti-depressant medication in the treatment of depression. *Behav Ther* 1982;13:133–144.
41. Rush AJ, Watkins JT. Group versus individual cognitive therapy: a pilot study. *Cogn Ther Res* 1981;5:95–103.
42. Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. *Am J Psychiatry* 1990;147:1493–1497.
43. Stravynski A, Verreault R, Gaudette G, Langlois R, Gagnier S, Larose M. The treatment of depression with group behavioural-cognitive therapy and imipramine. *Can J Psychiatry* 1994;39:387–390.
44. Weissman MM, Prusoff BA, Dimascio A, Neu C, Goklaney M, Klerman GL. The efficacy of drugs and psychotherapy in the treatment of acute depressive episodes. *Am J Psychiatry* 1979;136:555–558.
45. Zisook S, Peterkin J, Goggin KJ, Sledge P, Atkinson JH, Grant I. Treatment of major depression in HIV-seropositive men. *J Clin Psychiatry* 1998;59:217–224.
46. Rosenthal R, Rubin DB. A simple, general purpose display of magnitude of experimental effect. *J Educ Psychol* 1982;74:166–169.
47. Rosenthal R. How are we doing in soft psychology? *Am Psychol* 1990;45:775–777.
48. De Mello MF, Myczcowisk LM, Menezes PR. A randomized controlled trial comparing moclobemide and moclobemide plus interpersonal psychotherapy in the treatment of dysthymic disorder. *J Psychother Pract Res* 2001;10:117–123.
49. Macaskill ND, Macaskill A. Rational-emotive therapy plus pharmacotherapy versus pharmacotherapy alone in the treatment of high cognitive dysfunction depression. *Cogn Ther Res* 1996;20:575–592.
50. Bedi N, Chilvers C, Churchill R, Dewey M, Duggan C, Fielding K. Assessing effectiveness of treatment of depression in primary care: Partially randomised preference trial. *Br J Psychiatry* 2000;177:312–318.
51. Gaffan EA, Tsaousis I, Kemp-Wheeler SM. Researcher allegiance and meta-analysis: the case of cognitive therapy for depression. *J Consult Clin Psychol* 1995;63:966–980.
52. Wampold BE, Minami T, Baskin TW, Callen Tierney S. A meta-(re)analysis of the effects of cognitive therapy versus 'other therapies' for depression. *J Affect Dis* 2002;68:159–165.

Copyright of Depression & Anxiety (1091-4269) is the property of John Wiley & Sons Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.